Titan Other Current Assets vs Net Receivables Analysis
| TTNP Stock | USD 6.51 0.15 2.36% |
Titan Pharmaceuticals financial indicator trend analysis is much more than just breaking down Titan Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Titan Pharmaceuticals is a good investment. Please check the relationship between Titan Pharmaceuticals Other Current Assets and its Net Receivables accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Titan Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Titan Stock, please use our How to Invest in Titan Pharmaceuticals guide.
Other Current Assets vs Net Receivables
Other Current Assets vs Net Receivables Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Titan Pharmaceuticals Other Current Assets account and Net Receivables. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Titan Pharmaceuticals' Other Current Assets and Net Receivables is -0.32. Overlapping area represents the amount of variation of Other Current Assets that can explain the historical movement of Net Receivables in the same time period over historical financial statements of Titan Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Titan Pharmaceuticals' Other Current Assets and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Current Assets of Titan Pharmaceuticals are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Other Current Assets i.e., Titan Pharmaceuticals' Other Current Assets and Net Receivables go up and down completely randomly.
Correlation Coefficient | -0.32 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
Other Current Assets
Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.Net Receivables
Most indicators from Titan Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Titan Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Titan Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Titan Stock, please use our How to Invest in Titan Pharmaceuticals guide.At this time, Titan Pharmaceuticals' Sales General And Administrative To Revenue is relatively stable compared to the past year. As of 06/01/2024, Enterprise Value Over EBITDA is likely to grow to 0.0006, while Issuance Of Capital Stock is likely to drop slightly above 7.2 M.
Titan Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Titan Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Titan Pharmaceuticals fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 9.5M | 8.1M | 8.0M | 4.1M | 8.1M | 7.7M | |
| Short Long Term Debt Total | 4.4M | 809K | 299K | 187K | 565K | 536.8K | |
| Other Current Liab | 1.9M | 2.0M | 1.5M | 1.6M | 519K | 493.1K | |
| Total Current Liabilities | 3.6M | 4.2M | 2.7M | 2.6M | 1.4M | 1.4M | |
| Total Stockholder Equity | 1.4M | 3.5M | 5.1M | 1.4M | 6.6M | 6.3M | |
| Property Plant And Equipment Net | 1.2M | 759K | 717K | 407K | 68K | 64.6K | |
| Net Debt | (782K) | (4.6M) | (5.7M) | (2.8M) | (6.2M) | (6.5M) | |
| Retained Earnings | (349.0M) | (367.3M) | (376.1M) | (386.3M) | (391.8M) | (372.2M) | |
| Accounts Payable | 1.4M | 1.3M | 795K | 695K | 348K | 330.6K | |
| Cash | 5.2M | 5.4M | 6.0M | 2.9M | 6.8M | 8.3M | |
| Non Current Assets Total | 1.2M | 759K | 765K | 455K | 68.0K | 64.6K | |
| Non Currrent Assets Other | 794K | (1.2M) | (759K) | 48K | (1.0) | (0.95) | |
| Cash And Short Term Investments | 5.2M | 5.4M | 6.0M | 2.9M | 6.8M | 6.4M | |
| Net Receivables | 993K | 884K | 112K | 36K | 1.0M | 1.6M | |
| Common Stock Shares Outstanding | 1.3K | 188.7K | 486.5K | 671.7K | 752K | 789.6K | |
| Liabilities And Stockholders Equity | 9.5M | 8.1M | 8.0M | 4.1M | 8.1M | 7.7M | |
| Non Current Liabilities Total | 3.8M | 4.5M | 332K | 187K | 65K | 0.0 | |
| Other Stockholder Equity | 350.4M | 370.8M | 381.2M | 387.6M | 398.5M | 418.4M | |
| Total Liab | 8.1M | 4.6M | 2.9M | 2.7M | 1.4M | 1.4M | |
| Total Current Assets | 8.3M | 7.3M | 7.2M | 3.6M | 8.0M | 7.6M | |
| Short Term Debt | 272K | 477K | 112K | 122K | 565K | 1.1M | |
| Other Current Assets | 1.1M | 522K | 480K | 314K | 199K | 189.1K | |
| Property Plant And Equipment Gross | 1.2M | 618K | 2.1M | 2M | 774K | 883.3K | |
| Common Stock | 57K | 7K | 10K | 15K | 1K | 950.0 | |
| Property Plant Equipment | 794K | 1.2M | 759K | 717K | 824.6K | 826.4K | |
| Long Term Debt | 3.6M | 3.8M | 4.0M | 332K | 298.8K | 283.9K | |
| Retained Earnings Total Equity | (323.3M) | (332.6M) | (349.0M) | (367.3M) | (330.6M) | (347.1M) | |
| Net Tangible Assets | 6.8M | 1.4M | 3.5M | 5.1M | 4.6M | 4.7M | |
| Capital Surpluse | 26.3M | 339.4M | 350.4M | 370.8M | 426.4M | 447.7M | |
| Net Invested Capital | 5.5M | 4.2M | 5.1M | 1.4M | 7.1M | 4.8M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Titan Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Titan Stock, please use our How to Invest in Titan Pharmaceuticals guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Complementary Tools for Titan Stock analysis
When running Titan Pharmaceuticals' price analysis, check to measure Titan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Titan Pharmaceuticals is operating at the current time. Most of Titan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Titan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Titan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Titan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |
Is Titan Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Titan Pharmaceuticals. If investors know Titan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Titan Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.42) | Revenue Per Share 0.245 | Quarterly Revenue Growth (1.00) | Return On Assets (0.75) | Return On Equity (1.39) |
The market value of Titan Pharmaceuticals is measured differently than its book value, which is the value of Titan that is recorded on the company's balance sheet. Investors also form their own opinion of Titan Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Titan Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Titan Pharmaceuticals' market value can be influenced by many factors that don't directly affect Titan Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Titan Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Titan Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Titan Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.